Gufic Biosciences Financial Statements

Gufic Biosciences (GUFICBIO) reported revenue of ₹8.20B in FY2025 with net income of ₹696.49M. Total assets stood at ₹11.69B and free cash flow was ₹470.42M.

Gufic Biosciences Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		4.91B	7.82B	6.93B	8.09B	8.20B
Cost of Rev. Cost of Revenue		-2.50B	-4.12B	-3.32B	-3.90B	-3.75B
Gross Profit		2.41B	3.70B	3.61B	4.19B	4.45B
SGA Sales, General & Admin		-1.53B	-2.21B	-2.24B	-2.71B	-3.09B
Op. Income Operating Income		713.45M	1.32B	1.15B	1.31B	1.15B
PBT Profit Before Tax		577.12M	1.27B	1.07B	1.16B	941.44M
Net Income		442.32M	958.40M	797.05M	861.36M	696.49M
Dil. Shares Diluted Shares		96.94M	96.94M	96.94M	98.52M	100.28M
Diluted EPS		4.56	9.89	8.22	8.74	6.95

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Gufic Biosciences's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Gufic Biosciences Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		2.61B	3.21B	4.64B	6.00B	6.25B
Non-curr. assets Total non-current assets		1.31B	2.01B	3.97B	4.92B	5.45B
Total assets		3.92B	5.21B	8.61B	10.93B	11.69B
Curr. liabilities Total current liabilities		1.64B	1.86B	2.88B	3.72B	3.88B
Non-curr. liab. Total non-current liabilities		549.62M	658.82M	2.25B	1.88B	1.81B
Total liabilities		2.19B	2.52B	5.13B	5.60B	5.68B
Total equity		1.73B	2.69B	3.48B	5.33B	6.01B
Total liab. & eq. Total liabilities & equity		3.92B	5.21B	8.61B	10.93B	11.69B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Gufic Biosciences's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Gufic Biosciences Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		442.32M	958.40M	797.05M	861.36M	696.49M
Operating CF Cash flow Operating Activities		890.65M	1.06B	-265.87M	-74.57M	1.23B
Capex Investments in PPE		-141.78M	-874.53M	-1.88B	-1.13B	-755.26M
Investing CF Cash flow Investing Activities		-85.07M	-945.89M	-1.91B	-1.02B	-707.77M
Dividend Paid		-3.63M	-9.21M	-10.44M	-9.72M	-10.03M
Financing CF Cash flow Financing Activities		-786.18M	-62.44M	2.34B	823.81M	-372.04M
Cash (start) Cash at beginning of period		42.61M	62.01M	116.08M	286.02M	11.37M
Cash (end) Cash at end of period		62.01M	116.08M	286.02M	11.37M	157.23M
FCF Free Cash Flow		748.87M	187.86M	-2.14B	-1.20B	470.42M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Gufic Biosciences's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025